Biotech News Alert: GenSpera, Inc. (OTCQB:GNSZ) Featured in
TheStockRadio.com Interview
SAN ANTONIO - December 2, 2014 (Investorideas.com Biotech
Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing innovative prodrug
therapeutics for the treatment of cancer, releases a recent audio interview
with TheStockRadio.com. Craig Dionne, PhD, GenSpera's CEO, discusses the
company's background and history including the inception and development of the
company's lead compound, mipsagargin, at John Hopkins University and its
subsequent development by the company. Dr. Dionne also highlights the benefits
of mipsagargin over traditional chemotherapeutics, including its limited side
effects and more effective tumor killing properties.
Finally,
Dr. Dionne provides an update as to the company's current Phase II clinical
trials in liver cancer and glioblastoma (brain cancer) as well as future Phase
II clinical trials in prostate cancer and kidney cancer and possibly even lung
and breast cancers that have metastasized to the brain.
All information discussed has been publicly
disclosed in press releases and filings.
Learn more about TheStockRadio.com
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2014/12021.asp
About GenSpera
GenSpera's
technology platform combines a powerful, plant-derived cytotoxin (thapsigargin)
with a prodrug delivery system that provides for the targeted release of drug
candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin
results in cell death irrespective of the rate of cell division, which may
provide an effective approach to kill both fast- and slow-growing cancers.
GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA,
which is found at high levels in the vasculature of liver and glioblastoma
cancers and in the vasculature of almost all other solid tumors. Mipsagargin is
expected to have potential efficacy in a wide variety of tumor types.
The
US Food and Drug Administration (FDA) granted Orphan Drug designation in 2013
for the evaluation of mipsagargin in patients with hepatocellular carcinoma.
Mipsagargin Phase II clinical trials are underway in both hepatocellular
carcinoma (liver cancer) and glioblastoma patients (brain cancer).
For
more information, please visit the company's website: www.genspera.com or follow us on
Twitter @GenSperaNews.
Cautionary Statement Regarding
Forward Looking Information
This
news release may contain forward-looking statements. Investors are cautioned
that statements in this press release regarding potential applications of
GenSpera's technologies constitute forward-looking statements that involve
risks and uncertainties, including, without limitation, risks inherent in the
development and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need for future
capital, dependence upon collaborators and maintenance of our intellectual
property rights. Actual results may differ materially from the results
anticipated in these forward-looking statements. Additional information on
potential factors that could affect our results and other risks and
uncertainties will be detailed from time to time in GenSpera's periodic reports
filed with the Securities and Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
+1-813-926-8920
Media:
Dawn Van Zant
800-665-0411
800-665-0411
Disclaimer/Disclosure: Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera
(GNSZ) has engaged Investor Ideas for PR and news publication effective
June 18, 2014 (compensation of five thousand per month and average of eleven
thousand five hundred 144 shares per month)
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 – biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment